In silico designing breast cancer peptide vaccine for binding to MHC class I and II: A molecular docking study

@article{Mahdavi2016InSD,
  title={In silico designing breast cancer peptide vaccine for binding to MHC class I and II: A molecular docking study},
  author={Manijeh Mahdavi and Violaine Moreau},
  journal={Computational biology and chemistry},
  year={2016},
  volume={65},
  pages={110-116}
}
Antigenic peptides or cancer peptide vaccines can be directly delivered to cancer patients to produce immunologic responses against cancer cells. Specifically, designed peptides can associate with Major Histocompatibility Complex (MHC) class I or II molecules on the cell surface of antigen presenting cells activating anti-tumor effector mechanisms by triggering helper T cell (Th) or cytotoxic T cells (CTL). In general, high binding to MHCs approximately correlates with in vivo immunogenicity… CONTINUE READING